Procedures for application of the extended dosing after antitumor drug clinical trials

YANG Feng; HENG Jianfu; LIU Yi; TANG Qi; LI Kunyan

doi:10.11817/j.issn.1672-7347.2023.210739

您当前的位置：

首页 >

文章列表页 >

Procedures for application of the extended dosing after antitumor drug clinical trials

扫描看全文

Alert me when the article has been cited

提交

Perspective | 更新时间：2023-07-07

Procedures for application of the extended dosing after antitumor drug clinical trials
Procedures for application of the extended dosing after antitumor drug clinical trials
抗肿瘤药物临床试验受试者出组后延伸给药申请程序
Journal of Central South University. Medical Science Vol. 48, Issue 4, Pages: 508-515(2023)
作者机构：

1.湖南省肿瘤医院国家药物临床试验机构办公室，长沙 410013
作者简介：

杨凤，Email: yangfeng0711@126.com, ORCID: 0009-0007-8621-6556
李坤艳，Email: likunyan@hnca.org.cn, ORCID: 0009-0001-6805-9768
基金信息：

the Natural Science Foundation of Hunan Province(2020JJ9043);the Scientific Research Project of Hunan Provincial Health Commission(202213054878)
DOI：10.11817/j.issn.1672-7347.2023.210739
CLC：
CSTR：

YANG Feng, HENG Jianfu, LIU Yi, et al. Procedures for application of the extended dosing after antitumor drug clinical trials. [J]. Journal of Central South University. Medical Science 48(4):508-515(2023)
DOI：

YANG Feng, HENG Jianfu, LIU Yi, et al. Procedures for application of the extended dosing after antitumor drug clinical trials. [J]. Journal of Central South University. Medical Science 48(4):508-515(2023) DOI： 10.11817/j.issn.1672-7347.2023.210739.

摘要

新药临床试验已被癌症患者和医生公认为治疗癌症的积极方式，而延伸给药则是从临床试验退出后患者继续获得试验药物的一种特殊途径，国外已确立相关法规，但国内关于延伸给药管理办法未正式颁布，也无细则性文件指导延伸给药。目前各医疗机构临床试验用药物的延伸给药还处于摸索阶段，尚未建立一套健全且满足患者紧急用药需求的管理体系。本文结合湖南省肿瘤医院延伸给药实践经验，初步探索抗肿瘤药物临床试验受试者延伸给药的申请程序与伦理审查相关要求。在申请程序上建议明确各方职责，建立患者-医疗机构-申办者共同申请制度；伦理审查过程中建议在各方充分考量患者延伸给药的风险与获益后，再由伦理委员会综合评估决定是否批准延伸给药。

Abstract

New drug clinical trials have been considered as a positive way for treating cancer by cancer patients and doctors, and the extended dosing is a special way for patients’ withdrawal from antitumor clinical trials to obtain investigational new drugs. However, neither the regulations of expanded dosing nor the detail documents for expanded dosing have been officially published in China. At present, expanded dosing of investigational drugs is still at the exploratory stage in various medical institutions, and a complete management system has not been established to meet patients’ urgent needs for drug use. Based on the practical experience of extended dosing in Hunan Cancer Hospital, this paper preliminarily explored the application procedures and ethical review requirements of extended dosing for subjects in antitumor clinical trials. It is necessary to clarify the responsibilities of all patients in the procedure and establish a patient-medical institution-sponsor joint application system. In the process of ethical review, it is recommended that all parties fully consider the risks and benefits of extended dosing for patients, and then the ethics committee makes a comprehensive assessment to decide whether to approve extended dosing.

关键词

抗肿瘤药物临床试验延伸给药试验新药伦理审查

Keywords

antitumor drug clinical trialextended dosinginvestigational drugsethical review

references

Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1):17-48. http://doi.org/10.3322/caac.21763http://doi.org/10.3322/caac.21763.

Ulrich CM, Ratcliffe SJ, Zhou Q, et al. Association of perceived benefit or burden of research participation with participants’ withdrawal from cancer clinical trials[J/OL]. JAMA Netw Open, 2022, 5(11): e2244412 [2022-11-01]. https:// doi.org/10.1001/jamanetworkopen.2022.44412https://doi.org/10.1001/jamanetworkopen.2022.44412.

Unger JM, Cook E, Tai E, et al. The role of clinical trial participation in cancer research: barriers, evidence, and strategies[J]. Am Soc Clin Oncol Educ Book, 2016, 35: 185-198. https://doi.org/10.1200/EDBK_156686https://doi.org/10.1200/EDBK_156686.

Ulrich CM, Knafl K, Foxwell AM, et al. Experiences of patients after withdrawal from cancer clinical trials[J/OL]. JAMA Netw Open, 2021, 4(8): e2120052 [2022-11-01]. https://doi.org/10.1001/jamanetworkopen.2021.20052https://doi.org/10.1001/jamanetworkopen.2021.20052.

Li N, Huang HY, Wu DW, et al. Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review[J/OL]. Lancet Oncol, 2019, 20(11): e619-e626[2022-01-15]. https://doi.org/10.1016/S1470-2045(19)30491-7https://doi.org/10.1016/S1470-2045(19)30491-7.

Zhou Q, Chen XY, Yang ZM, et al. The changing landscape of clinical trial and approval processes in China[J]. Nat Rev Clin Oncol, 2017, 14(9): 577-583. https://doi.org/10.1038/nrclinonc. 2017.10https://doi.org/10.1038/nrclinonc.2017.10.

Comis RL, Miller JD, Aldigé CR, et al. Public attitudes toward participation in cancer clinical trials[J]. J Clin Oncol, 2003, 21(5): 830-835. https://doi.org/10.1200/JCO.2003.02.105https://doi.org/10.1200/JCO.2003.02.105.

Lansey DG, Hefka TA, Carducci MA, et al. Problem solving to enhance clinical trial participation utilizing a framework-driven approach[J]. Clin Adv Hematol Oncol, 2020, 18(8): 468-476.

De Panfilis L, Satolli R, Costantini M. Compassionate use programs in Italy: ethical guidelines[J]. BMC Med Ethics, 2018, 19(1): 22. https://doi.org/10.1186/s12910-018-0263-8https://doi.org/10.1186/s12910-018-0263-8.

Bunnik EM, Aarts N. What do patients with unmet medical needs want? A qualitative study of patients’ views and experiences with expanded access to unapproved, investigational treatments in the Netherlands[J]. BMC Med Ethics, 2019, 20(1): 80. https://doi.org/10.1186/s12910-019-0420-8https://doi.org/10.1186/s12910-019-0420-8.

唐密密, 梁宏岩, 杜洁, 等. 从瑞德西韦展望中国同情用药[J]. 中南大学学报(医学版), 2021, 46(8): 909-914. https://doi.org/10.11817/j.issn.1672-7347.2021.200255https://doi.org/10.11817/j.issn.1672-7347.2021.200255.

TANG Mimi, LIANG Hongyan, DU Jie, et al. Prospect of compassionate use in China from remdesivir[J]. Journal of Central South University. Medical Science, 2021, 46(8): 909-914. https://doi.org/10.11817/j.issn.1672-7347.2021.200255https://doi.org/10.11817/j.issn.1672-7347.2021.200255.

任磊, 张丽杨, 韩丹, 等. 澳大利亚药品特别准入计划对完善我国同情用药制度的启示[J]. 中国药房, 2020, 31(12): 1409-1413. https://doi.org/10.6039/j.issn.1001-0408.2020.12.01https://doi.org/10.6039/j.issn.1001-0408.2020.12.01.

REN Lei, ZHANG Liyang, HAN Dan, et al. Enlightenment of Australia’s drug special access scheme to the improvement of China’s sympathetic drug use system[J]. China Pharmacy, 2020, 31(12): 1409-1413. https://doi.org/10.6039/j.issn.1001-0408.2020.12.01https://doi.org/10.6039/j.issn.1001-0408.2020.12.01

刘丽华, 赵建中, 陈霞, 等. 美国拓展性用药和紧急授权使用制度的启示[J]. 中国临床药理学杂志, 2020, 36(7): 902-906. https://doi.org/10.13699/j.cnki.1001-6821.2020.07.050https://doi.org/10.13699/j.cnki.1001-6821.2020.07.050.

LIU Lihua, ZHAO Jianzhong, CHEN Xia, et al. Enlightenment of US regulations regarding expanded access to investigational drugs and emergency use authorization[J]. The Chinese Journal of Clinical Pharmacology, 2020, 36(7): 902-906, 925. https://doi.org/10.13699/j.cnki.1001-6821.2020.07.050https://doi.org/10.13699/j.cnki.1001-6821.2020.07.050.

陆海波. 论同情用药的立法价值取向及制度完善——以美国法为镜鉴[J]. 法学评论, 2022, 40(5): 126-134. https://doi.org/10.13415/j.cnki.fxpl.2022.05.011https://doi.org/10.13415/j.cnki.fxpl.2022.05.011.

LU Haibo. Discussion on the legislative value orientation and system improvement of compassionate drug use—Taking American law as a mirror[J]. Law Review, 2022, 40(5): 126-134. https://doi.org/10.13415/j.cnki.fxpl.2022.05.011https://doi.org/10.13415/j.cnki.fxpl.2022.05.011.

高杨, 梅丹, 李大魁, 等. 同情用药的国内外发展现状与思考[J]. 临床药物治疗杂志, 2020, 18(7): 88-92. https://doi.org/10.3969/j.issn.1672-3384.2020.07.020https://doi.org/10.3969/j.issn.1672-3384.2020.07.020.

GAO Yang, MEI Dan, LI Dakui, et al. Current situation and consideration of sympathetic medication in China and abroad[J]. Clinical Medication Journal, 2020, 18(7): 88-92. https://doi.org/10.3969/j.issn.1672-3384.2020.07.020https://doi.org/10.3969/j.issn.1672-3384.2020.07.020.

European Parliament, Council of the European Union. Regulation (EC) No 726/2004 [EB/OL].(2004-03-31)[2023-04-12]. https://eur-lex.europa.eu/search.html?scope=EURLEX&text=726%2F2004&lang=en&type=quick&qid=1685344301536https://eur-lex.europa.eu/search.html?scope=EURLEX&text=726%2F2004&lang=en&type=quick&qid=1685344301536.

韩桑莹, 姚军. 美国欧盟的“同情用药”制度及其对我国的启示[J]. 医学与法学, 2022, 14(1): 72-77.

HAN Sangying, YAO Jun. Compassionate use system in the United States and the European Union and Its Enlightenment to China[J]. Medicine & Jurisprudence, 2022, 14(1): 72-77.

蒋蓉, 张宁, 邵蓉. 欧盟临床试验药物拓展使用管理制度分析[J]. 中国新药与临床杂志, 2020, 39(5): 281-285. https://doi.org/10.14109/j.cnki.xyylc.2020.05.06https://doi.org/10.14109/j.cnki.xyylc.2020.05.06.

JIANG Rong, ZHANG Ning, SHAO Rong. Analysis of clinical trial drugs expanded access management system in Europe Union[J]. Chinese Journal of New Drugs and Clinical Remedies, 2020, 39(5): 281-285. https://doi.org/10.14109/j.cnki.xyylc.2020.05.06https://doi.org/10.14109/j.cnki.xyylc.2020.05.06.

中共中央办公厅、国务院办公厅. 中共中央办公厅国务院办公厅印发《关于深化审评审批制度改革鼓励药品医疗器械创新的意见》[EB/OL]. (2017-10-08)[2023-04-12]. http://www.gov.cn/zhengce/2017-10/08/content_5230105.htmhttp://www.gov.cn/zhengce/2017-10/08/content_5230105.htm.

The General Office of the Central Committee of the Communist Party of China, the General Office of the State Council. The General Office of the Central Committee of the Communist Party of China and the General Office of the State Council issued the “Opinions on deepening the reform of the examination and approval system and encouraging the innovation of pharmaceutical medical devices”[EB/OL]. (2017-10-08)[2023-04-12]. http://www.gov.cn/zhengce/2017-10/08/content_5230105.htmhttp://www.gov.cn/zhengce/2017-10/08/content_5230105.htm.

国家食品药品监管总局办公厅. 总局办公厅公开征求拓展性同情使用临床试验用药物管理办法（征求意见稿）意见[EB/OL]. (2017-12-15)[2023-04-15]. https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20171220170101778.htmlhttps://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20171220170101778.html.

General Office of China Food and Drug Administration. The General Office of China Food and Drug Administration has publicly solicited comments on the administrative measures for the extended compassionate use of drugs in clinical trials (draft for advice)[EB/OL]. (2017-12-15)[2023-05-18]. https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20171220170101778.htmlhttps://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20171220170101778.html.

第十三届全国人民代表大会常务委员会. 中华人民共和国药品管理法[EB/OL]. (2019-08-26)[2023-04-14]. http://www.gov.cn/xinwen/2019-08/26/content_5424780.htmhttp://www.gov.cn/xinwen/2019-08/26/content_5424780.htm.

The 13th NPC’s standing committee of China. The Drug Administration Law of the PRC[EB/OL]. (2019-08-26)[2023-04-14]. http://www.gov.cn/xinwen/2019-08/26/content_5424780. htmhttp://www.gov.cn/xinwen/2019-08/26/content_5424780.htm.

Borysowski J, Ehni HJ, Górski A. Ethics codes and use of new and innovative drugs[J]. Br J Clin Pharmacol, 2019, 85(3): 501-507. https://doi.org/10.1111/bcp.13833https://doi.org/10.1111/bcp.13833.

Borysowski J, Górski A. Compassionate use of unauthorized drugs: legal regulations and ethical challenges[J]. Eur J Intern Med, 2019, 65: 12-16. https://doi.org/10.1016/j.ejim.2019. 04.008https://doi.org/10.1016/j.ejim.2019.04.008.

江旻, 赵淑华, 吴大维, 等. 注册类抗肿瘤药物临床试验延伸给药共识(2019版)[J]. 中国新药杂志, 2020, 29(9): 1023-1026.

JIANG Min, ZHAO Shuhua, WU Dawei, et al. Consensus on the extended dosing after clinical trials of registered anti-cancer drugs (2019 Version)[J]. Chinese Journal of New Drugs, 2020, 29(9): 1023-1026.

国家药监局、国家卫生健康委. 国家药监局国家卫生健康委关于发布医疗器械拓展性临床试验管理规定(试行)的公告(2020年第41号)[EB/OL]. (2020-03-14)[2023-04-14]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20200320153801192.htmlhttps://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20200320153801192.html.

National Medical Products Administration, National Health Commission. Announcement of the National Medical Products Administration and National Health Commission on the Promulgation of Administrative Provisions on Extended Clinical Trials of Medical Devices (Trial) (No. 41 of 2020)[EB/OL]. (2020-03-14)[2023-04-14]. https://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20200320153801192.htmlhttps://www.nmpa.gov.cn/xxgk/fgwj/xzhgfxwj/20200320153801192.html.

Martinez R. Clinical trial outcomes: what matters to patients[J]. JACC Heart Fail, 2019, 7(3): 272-273. https://doi.org/10.1016/j.jchf.2018.12.003https://doi.org/10.1016/j.jchf.2018.12.003.

Montanaro N, Melis M, Proni S, et al. Six-year activity on approval of compassionate use of medicines by the Ethics Committee of the University Hospital of Bologna (Italy): time to update rules and recommendations[J]. Eur J Clin Pharmacol, 2017, 73(4): 479-485. https://doi.org/10.1007/s00228-016-2186-yhttps://doi.org/10.1007/s00228-016-2186-y.

Borysowski J, Górski A. Ethics framework for treatment use of investigational drugs[J]. BMC Med Ethics, 2020, 21(1): 116. https://doi.org/10.1186/s12910-020-00560-9https://doi.org/10.1186/s12910-020-00560-9.

赵晨阳, 杨焕, 高晨燕. 美国拓展性使用试验药物的现状及对我国的启示[J]. 中国新药杂志, 2019, 28(15): 1836-1840. https://doi.org/10.3969/j.issn.1003-3734.2019.15.009https://doi.org/10.3969/j.issn.1003-3734.2019.15.009.

ZHAO Chenyang, YANG Huan, GAO Chenyan. Overview of expanded access system in FDA and inspiration for China[J]. Chinese Journal of New Drugs, 2019, 28(15): 1836-1840. https:// doi.org/10.3969/j.issn.1003-3734.2019.15.009https://doi.org/10.3969/j.issn.1003-3734.2019.15.009.

Gerasimov E, Donoghue M, Bilenker J, et al. Before it’s too late: multistakeholder perspectives on compassionate access to investigational drugs for pediatric patients with cancer[J]. Am Soc Clin Oncol Educ Book, 2020, 40: 1-10. https://doi.org/10.1200/EDBK_278995https://doi.org/10.1200/EDBK_278995.

葛章志. 美国尝试权法案对临床试验用药物扩大使用制度的新发展[J]. 中国新药杂志, 2021, 30(2): 97-104.

GE Zhangzhi. The new development of the Right to Try Act on the expanded access of investigational new drugs in the USA[J]. Chinese Journal of New Drugs, 2021, 30(2): 97-104.

李艳蓉, 崔一民, 王海学, 等. 美国突发公共卫生事件医疗对策对我国药品审评审批和监管的启示[J]. 中国临床药理学杂志, 2020, 36(7): 907-911. https://doi.org/10.13699/j.cnki.1001-6821.2020.07.051https://doi.org/10.13699/j.cnki.1001-6821.2020.07.051.

LI Yanrong, CUI Yimin, WANG Haixue, et al. Enlightenment of American medical countermeasures policies on the drug evaluation, approval and management in response to public health emergencies in China[J]. The Chinese Journal of Clinical Pharmacology, 2020, 36(7): 907-911. https://doi.org/10.13699/j.cnki.1001-6821.2020.07.051https://doi.org/10.13699/j.cnki.1001-6821.2020.07.051.

Einstein DJ. Compassion and compassionate use[J]. J Clin Oncol, 2018, 36(29): 2969-2971. https://doi.org/10.1200/JCO. 18.00205https://doi.org/10.1200/JCO.18.00205.

谢泓怡, 刘佳举, 罗刚. 我国“同情用药” 法律制度之完善的研究: 以《拓展性同情使用临床试验用药物管理办法(征求意见稿)》为对象[J]. 医学与法学, 2022, 14(1): 78-83. https://doi.org/10.3969/j.issn.1674-7526.2022.01.014https://doi.org/10.3969/j.issn.1674-7526.2022.01.014.

XIE Hongyi, LIU Jiaju, LUO Gang. Research on the improvement of the legal system of compassionate use in China—taking expanded compassionate use management for clinical trials (draft for comments) as research object[J]. Medicine and Jurisprudence, 2022, 14(1): 78-83. https://doi.org/10.3969/j.issn.1674-7526.2022.01.014https://doi.org/10.3969/j.issn.1674-7526.2022.01.014.

Views

下载量

CSCD

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

Office of National Drug Clinical Trial Institution, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University

Postal code：410078
Tel：0731-84805495 Email：xyxb2005@vip.163.com
Technical support is provided by Beijing Founder electronics co., LTD 湘ICP备05005659号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰